APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
← catalyst calendarNCT06634394 · readout ≤ 438 d
Sponsored by Aptevo Therapeutics (industry) · APVO — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
39estimated
Sites
7
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-01 | actual | When the study began enrolling |
| Primary completion | Oct 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acute Myeloid Leukemia (AML)
Interventions
- Drug: APVO436
- Drug: Venetoclax — also filed as venclexta
- Drug: Azacitidine — also filed as vidaza
Primary outcome
what the primary-completion date above is the date OFTo assess the safety, tolerability, and maximum tolerated dose (MTD) of increasing doses of APVO436 in combination with venetoclax/azacitidine in patients with newly diagnosed AML
measured Through the end study completion average of 1 year.
Permalink · APVO's whole pipeline · Catalyst calendar · Every registered study · What changed